Various pre-clinical studies have underscored the potential protective effects of utilizing either a kinase-dead mutant of RIPK1 (RIPK1D138N) or pharmacological RIPK1 inhibitors in diverse neurodegenerative disease models. This evidence concerns the gene RIPK1 and neurodegenerative disease.